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A better understanding of key regulatory pathways perturbed
in cancers has led to the development of a molecularly
targeted therapeutic approach. As a result, new generations
of compounds aimed at inhibiting specific pathways that play
prominent roles in urological cancers have been developed
and continue to evolve. The possibility of being able to
perform molecular profiling in tumors would, at least in
theory, provide the clinician with information needed to
manage a personalized therapeutic regimen according to an
individual patient’s needs. While this modality is already
being implemented in other cancer fields, personalized
medicine for patients suffering from advanced lower urogen-
ital tumors is still in the developmental phase. This impetus
has prompted a concerted effort from investigators in the
fields of basic, translational, and clinical research to develop
and implement a tailored treatment approach. In this issue,
we present a collection of seven articles that contribute to our
knowledge of personalized medicine for urological cancers.
Androgen deprivation therapy (ADT) for advanced
prostate cancer is one of the earliest forms of targeted
therapy and has remained the choice of treatment by
physicians. Unfortunately, most patients will eventually
become non-responsive to ADT and succumb to the disease.
Since its inception, knowledge for the understanding of
androgen receptor (AR) signaling and mechanisms driving
the resistance to ADT has been significantly improved. As
a result, a new generation of therapeutic agents has been
developed. The paper by X. Hou and T. W. Flaig gives a
historical account of ADT for metastatic prostate cancer and
summarizes current advancements in hormonal therapies
using newly developed agents such as MDV3100, TOK-001,
and TAK-700.
The association between insulin and androgens in
prostate cancer progression is detailed by J. H. Gunter et al.
In this review, the authors describe the inverse relationship
between insulin and testosterone levels and the metabolic
crosstalk between the two signaling axes. The authors discuss
the effects of ADT-induced hyperinsulinaemia and describe
the direct effects of insulin on prostate tumor cells and its
clinical implications.
The 5 α-reductase inhibitors represent an important fam-
ily of enzymes that mediate the conversion of testosterone to
the more potent dihydrotestosterone (DHT). Consequently,
several compounds have been developed to inhibit the
activity of the enzymes to prevent and treat a number of
diseases. The paper by F. Azzouni et al. goes into great detail
to describe the basic biochemical properties and functions of
the 5 α-reductase isozyme family and its clinical significance
with regards to prostate cancer prevention and treatment.
Gene inactivation of PTEN is a common occurrence in
prostate cancers and is associated to metastatic potential,
androgen independence, and poor prognosis. The review by
M. A. De Velasco and H. Uemura chronicles the evolution
of the PTEN-deficient genetically engineered mouse (GEM)
and the cooperation between PTEN and other genetic
alterations that contribute to tumor progression. The authors
2 Advances in Urology
also describe the usefulness of GEM models for biomarker
and drug discovery.
Also in this issue, two reviews delve into the progress
towards personalized medicine for muscle invasive and
metastatic bladder cancer. J. S. Chang et al. review potential
molecular biomarkers currently under investigation and
discuss their future. In the second paper A. Kawashima
et al. review the excision repair cross-complementing group 1
(ERCC1) gene and its role in tumor development and thera-
peutic resistance to cytotoxic DNA-damaging chemotherapy
and ionizing radiation.
Finally, in the original paper by R. Nagarajan et al. the
authors use the apparent diffusion coefficient, derived from
diffusion-weighted (DWI) imaging, to identify higher-grade
prostate cancer lesions. Although the data is preliminary,
the authors’ findings reveal a potential for the use of
DWI imaging to differentiate those patients with high-grade
lesions.
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